St. Mary's Medical Center in West Palm Beach, Fla. closed its pediatric cardiothoracic surgery program after a CNN investigation revealed the program's high mortality rate. The Sun Sentinel reported that St. Mary's blamed "inaccurate media reports" for why it closed the program.

Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has entered into a corporate partnership with Fenway Park and will be bringing its Impella Mobile Learning Lab to the historic baseball stadium tomorrow.

A recent analysis painted an optimistic view on Medicare, a program that is divisive among politicians, healthcare professionals and the general public.

Pfizer will not be manufacturing an over-the-counter version of atorvastatin (Lipitor) after the company terminated its clinical trial program, Bloomberg reports. Since losing patent protection in 2011, sales of atorvastatin have decreased from more than $10 billion per year to $2.06 billion in 2014.

With the pending approval of two cholesterol-lowering drugs, the Washington Post reports concerns are mounting about the costs of the medications, which are both injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 

Novartis CEO Joe Jimenez told the Wall Street Journal that the company is considering offering add-on healthcare services to insurers concerned with the high costs of its newest drug. 

For 2016, health insurance companies are seeking rate increases of 20 percent to 40 percent, the New York Times reports. State insurance regulators are currently reviewing the requests.

In 2014, doctors and research hospitals collected $6.5 billion from pharmaceutical and medical device companies, Reuters reports. The figures were revealed in a report from the Centers for Medicare & Medicaid Services that listed information on payments that 1,444 companies made to 607,000 physicians and more than 1,100 teaching hospitals.